Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01080248 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01080248: Clinical Trial Phase 2 study, sponsored by Washington University School of Medicine.
NCT01080248 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01080248, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
To determine the response rate and survival of gemcitabine and pazopanib in patients with metastatic pancreatic cancer.
Primary Outcome
* Response rate = complete response + partial response per RECIST * Complete response - disappearance of all target and non-target lesions. * Partial response - at least a 30% decrease in the sum of the longest diameter of the target lesions, taking as reference the baseline sum longest diameter
Interventions
- DRUG Gemcitabine
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Why NCT01080248 stopped before completion
NCT01080248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT01080248 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01080248 about?
NCT01080248 is a clinical study titled "Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer". To determine the response rate and survival of gemcitabine and pazopanib in patients with metastatic pancreatic cancer.
What is the current status of trial NCT01080248?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2010-08. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01080248?
The interventions under investigation include: Gemcitabine (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01080248?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01080248's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia